A growth-focused global business executive, David has driven the industrialisation of Cell, Gene and Tissue therapies for almost 20 years. His performance track record across North America, Central Europe and Asia-Pacific includes supporting the manufacturing establishment of many of today’s commercial Cell & Gene Therapies.

David previously managed a global Cell Therapy automation business, leading a global team delivering commercial-scale manufacturing automation for the world’s leading biotherapeutics multinationals, developing bespoke manufacturing systems for emerging novel biotherapeutics at pre-clinical and early-clinical phases, and producing platform technologies for pioneering technology start-ups across the Cell Therapy landscape.

Initially a deeply technical engineer and scientist, David brings multi-sector leadership experience, including a period as a management consultant across industries as diverse as health, finance and primary industries, and has worked for and within businesses from Fortune 500s through start-ups. He focuses on establishing robust strategic, financial and operational foundations, from which to build powerful collaborations and drive meaningful change.

An infallible advocate for robust data-driven development of Cell & Gene Therapies, Jon is a cell biologist with 20 years’ experience in the production, development, and manufacturing establishment of Cell, Gene and Tissue therapies. His expertise spans R&D into new modality therapeutics and production processes, novel technology development for Cell Therapy manufacture, and the establishment through ongoing management of GMP biologic manufacturing.

Jon previously managed the US operations of a global Cell Therapy consulting business, leading a process development team and translation lab assessing and refining client manufacturing processes across novel automation pathways. Early in his career in the UK, Jon managed a large-scale cord blood and bone marrow transplantation laboratory, overseeing the delivery of GMP cell therapeutics to patients across 10 years. He moved to the US to focus on the development of new technologies for Cell & Gene Therapy manufacturing.

An author on multiple patents, Jon thrives at the intersection of process and product development for Cell & Gene Therapies, transitioning emerging novel technologies to market application. He brings first-hand experience across isolation, gene modification and expansion of cell types including T, NK, CD34, and MSCs, and has developed processes using today’s state of the art of Cell & Gene Therapy manufacturing systems. Jon has collaborated with many of the world’s leading therapy developers, from start-ups to multinationals, and is driven to elevate the manufacturing of Cell & Gene Therapies by automating and simplifying production processes to improve patient.

Defined by his fastidious attention to engineering detail, Mark has pushed the boundaries of new product development for almost 20 years. Teams under his guidance have twice been awarded Australia’s prestigious Good Design Award for biotech manufacturing systems. Mark brings a track record of success in evolving conceptual designs into quality manufacturable products within highly regulated environments.

Mark operated a project management office covering design and contract manufacture of life-science diagnostic and point-of-care devices, and previously spent 10 years developing next-generation Cell & Gene Therapy manufacturing systems for clients across the world, from large-scale allogeneic installations to point-of-care autologous manufacture. Mark’s pursuit of manufacturing excellence was forged in the automotive industry, managing future product design for advanced drivetrain systems including hybrid electric vehicles. He also established and operated a successful business in the automotive sector over a10-year growth trajectory.

Finessing the human experience is core to Mark’s approach, enabling his deep knowledge of complex engineering tools, techniques and systems to coalesce into automation systems of sophisticated simplicity. Mark brings a passion for leveraging great design to positively impact patient access to Cell & Gene Therapies.